EDAP TMS SA Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on September 9, 2025, presents an investor presentation for EDAP TMS SA, a French company specializing in therapeutic ultrasound. The financial data covers the three months ended June 30, 2025, and the six months ended June 30, 2025. The company is transitioning from a distributor model to becoming the global leader in Robotic HIFU (High-Intensity Focused Ultrasound) Focal Therapy, primarily targeting prostate cancer, Benign Prostatic Hyperplasia (BPH), and endometriosis.
Key Financial Metrics
| Metric (in $ Million USD) | Q2 2025 | Q2 2024 |
|---|---|---|
| Revenue | 18.4 | 17.0 |
| Gross Profit | 7.8 | 6.4 |
| Gross Margin | 42.5% | 37.5% |
| Operating Profit (Loss) | (6.6) | (6.6) |
| Net Income (Loss) | (6.4) | (6.6) |
| Earnings Per Share | (0.17) | (0.18) |
Revenue Breakdown (Q2 2025): HIFU ($5.2M), ESWL ($2.5M), Distribution ($9.4M).
Liquidity (as of June 30, 2025): Cash and Cash Equivalents were $19.1 million. Total Current Assets were $41.4 million against Current Liabilities of $40.2 million. Shareholders' Equity stood at $32.7 million.
Material Changes and Growth Drivers
- Revenue Growth: Total revenue increased 8.2% year-over-year. HIFU revenue grew significantly, while ESWL and Distribution revenues declined by 27% and 26% respectively, reflecting the strategic shift away from legacy technologies.
- Margin Expansion: Gross margin improved by 500 basis points to 42.5%, driven by the higher-margin HIFU business mix.
- Install Base: The U.S. Focal One install base reached 73 systems by the end of Q2 2025 (36 academic, 37 community). This represents a 50% CAGR in the U.S. install base from H1 2022 to H1 2025.
- Procedure Volume: U.S. Focal One procedures grew at a 52% CAGR over the same period.
Outlook, Clinical Evidence, and Risks
Clinical Evidence: The filing highlights the HIFI study (published Dec 2024), a prospective multicentric trial showing HIFU has comparable cancer control (90% STFS) to Radical Prostatectomy (86%) with superior functional outcomes (urinary continence and erectile function). The FARP randomized controlled trial also demonstrated equivalent oncologic control at 3 years with superior functional outcomes for focal ablation.
Reimbursement: CMS maintained HIFU at APC Level 6 for 2025, with a 90% reimbursement increase noted in 2023. Medicare payment for HIFU procedures is listed at $12,992 (hospital) and $951 (physician) for 2025.
Expansion Opportunities: The company is advancing clinical studies for BPH (Phase I-II recruiting) and Endometriosis (Phase III enrollment completed March 2025; CE mark obtained for posterior deep endometriosis).
Risks and Contingencies: The company remains unprofitable with a net loss of $6.4M for the quarter. Continued investment in R&D and commercialization is required to achieve profitability. Success depends on the adoption of robotic HIFU technology and the maintenance of favorable reimbursement rates.
Investor Verification Checklist
- Verify the sustainability of the 42.5% gross margin as the company scales HIFU sales and reduces distribution revenue.
- Confirm the timeline for profitability given the current operating loss of $6.6M per quarter.
- Monitor the results of the ongoing Phase III Endometriosis trial and the Phase I-II BPH study to validate expansion into these new indications.
- Assess the impact of the declining ESWL and Distribution segments on total revenue growth if HIFU adoption slows.
- Review the cash burn rate relative to the $19.1M cash balance to determine runway without additional financing.